Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 54.48% | -72.86% | -128.92% | -198.13% | -147.31% |
| Total Depreciation and Amortization | 1,253.57% | 807.14% | 371.43% | 61.11% | -3.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -166.98% | 1,332.04% | 340.17% | 255.25% | 266.38% |
| Change in Net Operating Assets | 67.23% | -119.06% | -112.15% | 13.32% | -70.05% |
| Cash from Operations | 1.83% | -17.64% | -25.03% | -8.05% | -26.01% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 16,005.15% | -12.86% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 12,377.81% | 40,072.41% | -16.25% | -- |
| Foreign Exchange rate Adjustments | 339.30% | 310.54% | 98.06% | -30.63% | -135.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 147.97% | 155.88% | 131.84% | -47.79% | -221.12% |